✓
Open
10 Dec 2025
✓
Close
12 Dec 2025
3
Allotment
—
✓
Listing
Wed, Dec 17, 2025
Price Band
₹438 to ₹460
Issue Size
1,89,43,020 shares (agg. up to ₹871 Cr)
Lot Size
32 Shares
Listing Date
Wed, Dec 17, 2025
Latest GMP
₹40
Est. Gain
8.7%
✦ AI Insight
GMP Trend
17-12-2025₹40Est. ₹500+8.7%
16-12-2025₹37Est. ₹497+8.04%
15-12-2025₹37Est. ₹497+8.04%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 10.12x |
Restated Financials (₹ Cr.)
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,193.68 | 996.46 | 806.02 | 666.23 |
| Total Income | 483.97 | 769.92 | 574.72 | 443.26 |
| Profit After Tax | 14.23 | 67.10 | 35.13 | -11.79 |
| EBITDA | 110.31 | 166.64 | 99.66 | 48.60 |
| NET Worth | 716.06 | 594.21 | 423.55 | 384.73 |
| Reserves and Surplus | 704.14 | 578.68 | 408.57 | 383.50 |
| Total Borrowing | 207.04 | 225.80 | 243.37 | 196.21 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Invicta Diagnostic Ltd. | SME | ₹28.12 Cr | ₹85 | 14.51 | ₹96.70 | +13.76% | ₹68.50 (+0.74%) |
| Star Imaging & Path Lab Ltd. | SME | ₹69.47 Cr | ₹142 | 12.01 | ₹135.95 | -4.26% | ₹95.48 (-0.59%) |
| Chandan Healthcare Ltd. | SME | ₹107.27 Cr | ₹159 | 19.44 | ₹173.35 | +9.03% | ₹241.50 (-1.71%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital expenditure by the Company for opening new dialysis clinics in India | 129.11 |
| 2 | Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company | 136.00 |
| 3 | General Corporate Purposes | 60.05 |
| 4 | Issue Expenses | 70.58 |
| Total | 395.73 |
About Nephrocare Health IPO
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets. The company offers services including diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy. As of Sep 30, 2025, Nephrocare operated 519 clinics with 51 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 288 cities in 21 States and 4 Union Territories. Approximately 77.53% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions. During Fiscal 2025, Nephrocare served 29,281 patients and completed 2,885,450 dialysis treatments, accounting for roughly 10% of the country's total dialysis patient base. Additionally, by Sep 30, it has served 31,046 patients and completed 1,591,377 treatments in India. As of Sep 30, 2025, the company has 5,562 dialysis machines. Nephrocare has formed strategic partnerships with established hospital chains such as Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospi
Contact Details
Nephrocare Health Services Ltd. Address5 th Floor, D Block, iLabs CentrePlot 18, Software Units LayoutSurvey No.64, Madhapur, ShaikpetHyderabad, Telangana, 500081+91 40 4240 8039cs@nephroplus.comVisit Website